Zogenix (ZGNX) Misses Q4 EPS by 11c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Tech stocks pull Wall Street lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2016 Financial Results
March 9, 2017 4:01 PM ESTTop-Line Data for First Phase 3 Study Expected in 3Q 2017
ZX008 Phase 3 Pivotal Study 1504 Initiated Target Data Readout by End of 2017
Planned Initiation of Phase 3 study of ZX008 in Lennox Gastaut Syndrome in 2H 2017
Company will host a conference call today at 4:30 p.m. EST/1:30 p.m. PST
EMERYVILLE, Calif., March 09, 2017 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a pharmaceutical company developing therapies for the treatment of orphan and central nervous system (CNS) disorders, today provided a... More
